Company

GenCART — Clinical-Stage Biotech in Pittsburgh, PA

GenCART is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, developing novel, patient-centric approaches to CAR-T therapy for blood cancers and autoimmune disorders. Born from the lessons of the pandemic, we’re re-engineering how cellular therapies are discovered, manufactured, and delivered—so that access is faster, safer, and closer to every patient who needs it.

Our Vision

A world where transformative cell therapies are reliable, local, and equitable—not limited by distance or fragile supply chains. We believe proximity and smart engineering shorten the path from order to infusion, improving outcomes and broadening eligibility.

What We’re Building

  • Decentralized manufacturing that brings production closer to care sites, reducing wait times and logistic risks.
  • Next-generation platforms exploring virus-free and advanced delivery methods to enhance safety and consistency.
  • Therapies for real-world use, designed for community and regional centers—not only flagship hospitals.
  • Broad disease focus: leading programs in B-cell lymphomas and an R&D path in autoimmune diseasesincluding SLE, RA, and MS.

Goals That Guide Us

  1. Access — Make CAR-T feasible anywhere, not 3,000 miles away.
  2. Speed — Compress timelines from referral to infusion.
  3. Safety & Quality — Engineer platforms that reduce known vector-related risks and standardize product quality.
  4. Scalability — Enable multi-site deployment without sacrificing rigor or reproducibility.
  5. Impact — Serve first-line high-risk, relapsed, and post-CAR-T failure populations with next-gen options.

Why Pittsburgh

Pittsburgh’s integrated ecosystem of academic medicine, engineering, and manufacturing excellence makes it the ideal home for a company marrying cutting-edge science with practical delivery.

GenCART is advancing a pipeline that reflects this commitment—moving leading programs through early clinical development while expanding a robust pre-clinical portfolio—so that breakthroughs reach patients faster, safely, and at scale.